文献速递淋巴瘤白血病

靶向成人T细胞白血病/淋巴瘤中GARP-TGF-β轴的双向抗肿瘤与免疫策略

Bidirectional anti-tumor and immunological strategies by targeting GARP-TGF-β axis in adult T-cell leukemia/lymphoma.
PubMed 文献 · Leukemia · 2025-08-04

研究利用成人T细胞白血病/淋巴瘤(ATL)细胞的调节性T细胞(Treg)样表型,通过全转录组筛选发现GARP是ATL新型肿瘤抗原。GARP-TGF-β轴促进ATL细胞及HTLV-1感染细胞增殖并抑制效应T细胞活性,抗GARP单克隆抗体DS-1055a通过抗体依赖细胞介导的细胞毒作用选择性清除恶性ATL细胞,在临床前研究中支持该概念验证。

要点

  • GARP在ATL细胞中过表达并释放TGF-β,是ATL的新型肿瘤抗原。
  • GARP-TGF-β轴促进ATL细胞及HTLV-1感染细胞增殖,并抑制周围效应T细胞活性。
  • 抗GARP单克隆抗体DS-1055a通过ADCC选择性清除恶性ATL细胞,临床前研究支持概念验证。

核心结论

  • 靶向GARP可同时实现直接清除肿瘤细胞和间接激活免疫的双重治疗效果,为ATL提供突破性治疗概念。

研究设计与样本

  • 研究利用原代ATL细胞的全转录组数据进行筛选,寻找有效治疗靶点,并在临床前研究中验证抗GARP抗体的概念。

主要发现

  • GARP被鉴定为ATL的新型肿瘤抗原,ATL细胞过表达GARP并释放TGF-β。
  • GARP-TGF-β轴通过改变细胞信号活性及塑造Treg基因表达模式,促进ATL细胞和HTLV-1感染细胞增殖。
  • GARP-TGF-β轴抑制周围效应T细胞的活性。
  • 抗GARP单克隆抗体DS-1055a通过抗体依赖细胞介导的细胞毒作用选择性且有效地清除恶性ATL细胞。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

In adult T-cell leukemia/lymphoma (ATL), tumor cells show a regulatory T-cell (Treg)-type phenotype, which influences their tumor immunity. However, our knowledge of what molecular events are involved in pathogenesis is still missing. Here, we took advantage of this unique phenotype and screened whole transcriptome data from primary ATL cells to search for effective therapeutic targets. Glycoprotein A repetitions predominant (GARP) was identified as a novel tumor antigen in ATL. ATL cells overexpress GARP and release transforming growth factor-β (TGF-β). The GARP-TGF-β axis promotes cell proliferation of ATL cells and human T-cell leukemia virus type 1 (HTLV-1)-infected cells with changes in cell signaling activities and shaping of Treg gene expression patterns, but suppresses the activity of surrounding effector T-cells. Remarkably, this study has provided a breakthrough therapeutic concept that achieves the dual effect of direct tumor cell depletion and indirect immune activation by a single treatment targeting GARP. DS-1055a, an anti-GARP monoclonal antibody, selectively and effectively depleted malignant ATL cells via antibody-dependent cellular cytotoxicity, supporting the proof-of-concept in the preclinical study. Our findings highlight the key to understanding the cell origin of ATL and developing unprecedented therapeutic strategies for refractory diseases.

来源:Leukemia,查看原文。版权归原作者所有。

引用

  1. Suzuki K, Kusayanagi S, Kuze Y, et al. Bidirectional anti-tumor and immunological strategies by targeting GARP-TGF-β axis in adult T-cell leukemia/lymphoma. Leukemia. 2025. PMID: 40759773. doi:10.1038/s41375-025-02725-0

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。